a public good project by the
Synthesis
Company
of California

© 2026

Elza C. de Bruin | doi.page

0 works0 citations0 h-index

Elza C. de Bruin

AstraZeneca (United Kingdom)(GB)AstraZeneca (Australia)(AU)AstraZeneca (Singapore)(SG)

Publications by Year

Research Areas

PI3K/AKT/mTOR signaling in cancer, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Advanced Breast Cancer Therapies, Renal cell carcinoma treatment

Most-Cited Works

→ Spatial and temporal diversity in genomic instability processes defines lung cancer evolution(2014)1,155 cited
→ Clonal status of actionable driver events and the timing of mutational processes in cancer evolution(2015)707 cited
→ Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial(2019)380 cited
→ Apoptosis and non-apoptotic deaths in cancer development and treatment response(2008)273 cited
→ Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine(2014)226 cited
→ Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer(2014)208 cited

→ A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers(2017)

143 cited

→ Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer(2022)136 cited

→ Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution(2015)121 cited

→ Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer(2020)99 cited